Cargando…

Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015

BACKGROUND: Childhood tuberculosis (TB) diagnoses often lack microbiologic confirmation and require empiric treatment. Barriers to empiric treatment include concern for poor outcomes and adverse effects. We thus determined the outcomes of empiric TB treatment from a retrospective cohort of children...

Descripción completa

Detalles Bibliográficos
Autores principales: Wobudeya, Eric, Jaganath, Devan, Sekadde, Moorine Penninah, Nsangi, Betty, Haq, Heather, Cattamanchi, Adithya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489192/
https://www.ncbi.nlm.nih.gov/pubmed/31035984
http://dx.doi.org/10.1186/s12889-019-6821-2
_version_ 1783414770483855360
author Wobudeya, Eric
Jaganath, Devan
Sekadde, Moorine Penninah
Nsangi, Betty
Haq, Heather
Cattamanchi, Adithya
author_facet Wobudeya, Eric
Jaganath, Devan
Sekadde, Moorine Penninah
Nsangi, Betty
Haq, Heather
Cattamanchi, Adithya
author_sort Wobudeya, Eric
collection PubMed
description BACKGROUND: Childhood tuberculosis (TB) diagnoses often lack microbiologic confirmation and require empiric treatment. Barriers to empiric treatment include concern for poor outcomes and adverse effects. We thus determined the outcomes of empiric TB treatment from a retrospective cohort of children at a national referral hospital in Kampala, Uganda from 2010 to 2015. METHODS: Children were diagnosed clinically and followed through treatment. Demographics, clinical data, outcome and any adverse events were extracted from patient charts. A favorable outcome was defined as a child completing treatment with clinical improvement. We performed logistic regression to assess factors associated with loss to follow up and death. RESULTS: Of 516 children, median age was 36 months (IQR 15–73), 55% (95% CI 51–60%) were male, and HIV prevalence was 6% (95% CI 4–9%). The majority (n = 422, 82, 95% CI 78–85%) had a favorable outcome, with no adverse events that required treatment discontinuation. The most common unfavorable outcomes were loss to follow-up (57/94, 61%) and death (35/94, 37%; overall mortality 7%). In regression analysis, loss to follow up was associated with age 10–14 years (OR 2.38, 95% CI 1.15–4.93, p = 0.02), HIV positivity (OR 3.35, 95% CI 1.41–7.92, p = 0.01), hospitalization (OR 4.14, 95% CI 2.08–8.25, p < 0.001), and living outside of Kampala (OR 2.64, 95% CI 1.47–4.71, p = 0.001). Death was associated with hospitalization (OR 4.57, 95% CI 2.0–10.46, p < 0.001), severe malnutrition (OR 2.98, 95% CI 1.07–8.27, p = 0.04), baseline hepatomegaly (OR 4.11, 95% CI 2.09–8.09, p < 0.001), and living outside of Kampala (OR 2.41, 95% CI 1.17–4.96, p = 0.02). CONCLUSIONS: Empiric treatment of child TB was effective and safe, but treatment success remained below the 90% target. Addressing co-morbidities and improving retention in care may reduce unfavorable outcomes.
format Online
Article
Text
id pubmed-6489192
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64891922019-06-05 Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015 Wobudeya, Eric Jaganath, Devan Sekadde, Moorine Penninah Nsangi, Betty Haq, Heather Cattamanchi, Adithya BMC Public Health Research Article BACKGROUND: Childhood tuberculosis (TB) diagnoses often lack microbiologic confirmation and require empiric treatment. Barriers to empiric treatment include concern for poor outcomes and adverse effects. We thus determined the outcomes of empiric TB treatment from a retrospective cohort of children at a national referral hospital in Kampala, Uganda from 2010 to 2015. METHODS: Children were diagnosed clinically and followed through treatment. Demographics, clinical data, outcome and any adverse events were extracted from patient charts. A favorable outcome was defined as a child completing treatment with clinical improvement. We performed logistic regression to assess factors associated with loss to follow up and death. RESULTS: Of 516 children, median age was 36 months (IQR 15–73), 55% (95% CI 51–60%) were male, and HIV prevalence was 6% (95% CI 4–9%). The majority (n = 422, 82, 95% CI 78–85%) had a favorable outcome, with no adverse events that required treatment discontinuation. The most common unfavorable outcomes were loss to follow-up (57/94, 61%) and death (35/94, 37%; overall mortality 7%). In regression analysis, loss to follow up was associated with age 10–14 years (OR 2.38, 95% CI 1.15–4.93, p = 0.02), HIV positivity (OR 3.35, 95% CI 1.41–7.92, p = 0.01), hospitalization (OR 4.14, 95% CI 2.08–8.25, p < 0.001), and living outside of Kampala (OR 2.64, 95% CI 1.47–4.71, p = 0.001). Death was associated with hospitalization (OR 4.57, 95% CI 2.0–10.46, p < 0.001), severe malnutrition (OR 2.98, 95% CI 1.07–8.27, p = 0.04), baseline hepatomegaly (OR 4.11, 95% CI 2.09–8.09, p < 0.001), and living outside of Kampala (OR 2.41, 95% CI 1.17–4.96, p = 0.02). CONCLUSIONS: Empiric treatment of child TB was effective and safe, but treatment success remained below the 90% target. Addressing co-morbidities and improving retention in care may reduce unfavorable outcomes. BioMed Central 2019-04-29 /pmc/articles/PMC6489192/ /pubmed/31035984 http://dx.doi.org/10.1186/s12889-019-6821-2 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wobudeya, Eric
Jaganath, Devan
Sekadde, Moorine Penninah
Nsangi, Betty
Haq, Heather
Cattamanchi, Adithya
Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
title Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
title_full Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
title_fullStr Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
title_full_unstemmed Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
title_short Outcomes of empiric treatment for pediatric tuberculosis, Kampala, Uganda, 2010–2015
title_sort outcomes of empiric treatment for pediatric tuberculosis, kampala, uganda, 2010–2015
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489192/
https://www.ncbi.nlm.nih.gov/pubmed/31035984
http://dx.doi.org/10.1186/s12889-019-6821-2
work_keys_str_mv AT wobudeyaeric outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015
AT jaganathdevan outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015
AT sekaddemoorinepenninah outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015
AT nsangibetty outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015
AT haqheather outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015
AT cattamanchiadithya outcomesofempirictreatmentforpediatrictuberculosiskampalauganda20102015